COMPASS Pathways plc Q2 2026 Earnings Recap

CMPS Q2 2026 August 10, 2026

Get alerts when CMPS reports next quarter

The stock surged 14.8% following the quarter, reflecting strong investor enthusiasm around COMPASS Pathways' highly statistically significant Phase III trial results for COMP360 and clear progress toward an NDA filing and launch readiness.

Earnings Per Share Miss

$-1.88 vs $-0.46 est.

-308.7% surprise

Market Reaction

1-Day +1.52%

5-Day +2.05%

See CMPS alongside your other holdings

Add to your portfolio — free

Key Takeaways

Reported positive Phase III primary endpoint results demonstrating rapid and durable efficacy in treatment-resistant depression (TRD).
NDA rolling submission is underway with completion expected in Q4 2026 and potential for accelerated FDA approval.
Robust cash position of $433 million supports operations through launch and into 2028.
Commercial team fully built out with extensive launch experience; active preparations for sales force recruitment and market readiness.
Plans to leverage existing interventional psychiatry infrastructure (8,000+ sites), facilitating a smoother market entry.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CMPS on AllInvestView.

Previous Q1 2026